Status:

COMPLETED

Good Choice of pALliative Chemotherapy to Patient With Pancreatic Cancer ; GemcitAbine Therapy vs FOLFORINOX therapY

Lead Sponsor:

Boryung Pharmaceutical Co., Ltd

Conditions:

Locally Advanced Pancreatic Cancer

Metastatic Pancreatic Cancer

Eligibility:

All Genders

19+ years

Brief Summary

The study objectives are to find out: 1) palliative chemotherapy patterns and prognosis in patients with locally advanced or metastatic pancreatic cancer in Korea's real clinical settings, and 2) reas...

Detailed Description

This study is a domestic, multi-center, prospective, observational study designed for locally advanced or metastatic pancreatic cancer patients who plan to receive palliative chemotherapy. When patien...

Eligibility Criteria

Inclusion

  • Patients are briefed about the study objectives and methodologies, and express their consent by signing a written agreement for the use of their personal information.
  • Male and female adults who are ≥ 19 years old at the time of enrollment.
  • Locally advanced or metastatic pancreatic cancer patients whose diagnosis was confirmed histologically or cytologically.
  • Patients who plan to receive palliative chemotherapy (e.g., FOLFIRINOX, Gemcitabine-based therapy, etc.)

Exclusion

  • Patients who are diagnosed with any other primary cancer that may influence pancreatic cancer treatment or prognosis.
  • Patients who are currently or have a history of receiving palliative chemotherapy.
  • Female patients who are pregnant, have childbearing potential or are breastfeeding.
  • Patients who are currently participating in other clinical trials (clinical trials for drugs or medical devices) or are planning to participate in other clinical trials during the study period. However, patients participating in a non-interventional observational study or registry study can be enrolled.
  • Other patients who are judged by the investigator to be ineligible to participate in the study.

Key Trial Info

Start Date :

January 29 2021

Trial Type :

OBSERVATIONAL

Allocation :

ACTUAL

End Date :

June 24 2025

Estimated Enrollment :

799 Patients enrolled

Trial Details

Trial ID

NCT04789980

Start Date

January 29 2021

End Date

June 24 2025

Last Update

September 12 2025

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

The Catholic University of Korea, Seoul St. Mary's Hospital

Seoul, South Korea

Good Choice of pALliative Chemotherapy to Patient With Pancreatic Cancer ; GemcitAbine Therapy vs FOLFORINOX therapY | DecenTrialz